Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


ProNAi Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting

PLYMOUTH, Mich., Nov. 9, 2012 /PRNewswire-USNewswire/ -- ProNAi Therapeutics, Inc., a private DNAi cancer drug development company, recently concluded its initial human clinical trial of PNT2258, a first-in-class, nucleic acid drug.  It is presenting the results of the Phase I study of PNT2258, an anti-Bcl-2 cancer drug, at the annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, a conference hosted by the European Organization for Research and Treatment of Cancer, the National Cancer Institute and the American Association for Cancer Research.

The company also expanded its management team with the recent appointments of board member and venture capital investor Mina Sooch, MBA, as President and CEO, and Dr. Richard Messmann, M.D., as Chief Medical Officer.

"The encouraging clinical results from our 22 patient study, conducted at START in Texas, showed we can achieve exposure levels in humans that were many times the level needed to achieve anti-tumor effect in animals without significant liver or blood platelet toxicity.  We also demonstrated statistically significant, dose-dependent, and specific knockdown of the Bcl-2 gene with suppression of protein levels up to 60 percent," said Dr. Messmann.  "Patients received the drug for extended periods of time without having material side effects seen with other anti-Bcl-2 drugs or nucleic acid cancer drugs in development.  These results indicate that we can administer the drug either as a single agent or potentially in combination with other anti-cancer drugs without adding patient side effects."

"PNT2258 represents the first of many targeted drugs in ProNAi's portfolio that utilize its emerging DNA interference platform called DNAi," added Sooch.  "We look forward to rapidly expanding PNT2258's clinical development to confirm efficacy in patients with Bcl-2-driven tumors, such as diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia.  We also anticipate eventual development into other solid tumors such as cancers of the lung, head and neck, and sarcomas.  ProNAi continues to pursue both venture capital funding and partnerships with pharmaceutical companies to advance these promising potential therapies for cancer.  ProNAi is proud to be a pioneer in nucleic acid therapeutics by overcoming the drug delivery challenges of RNA and DNA based therapies as it has demonstrated safe and effective systemic delivery beyond the liver in humans."

Prior to joining ProNAi, Mina Sooch, who has more than 20 years of experience in pharmaceuticals, healthcare, and M&A after receiving her MBA from Harvard University, helped co-found Apjohn Ventures Fund and several biotech start-ups.  Dr. Messmann, who has over 20 years extensive clinical experience as a medical oncologist and drug-development physician, recently served as Vice President of Medical Affairs for Endocyte [ECYT] where he led the development of vintafolide for ovarian cancer through successful late stage clinical trials.  The executive management team is rounded out by Dr. Wendi Rodrigueza, Chief Scientific Officer (formerly Novartis, Curagen, and Esperion), and ProNAi scientific advisors, led by Dr. Bruce Zetter of Harvard Medical School.

About PNT2258
PNT2258 is a 24-mer, single stranded, chemically unmodified (i.e., native) DNA oligonucleotide sequence called PNT100 encapsulated in a specialized anionic and pH "tunable" liposome.  PNT2258, which is delivered via a 2 hour infusion, has a long half-life of several days allowing it to infiltrate cancer cells, release into the nucleus, and initiate apoptosis by silencing the Bcl-2 target gene.

About ProNAi
ProNAi Therapeutics Inc. is a venture backed biotechnology company based in Plymouth and Kalamazoo, Michigan.  The novel DNAi drug platform is proprietary to ProNAi.  Unlike many RNA products (antisense, RNAi, microRNA, etc) that work in the cytoplasm of a cell, DNAi drugs are designed to target sequences that reside in the non-coding regions of the genome and block transcription in the nucleus, thereby silencing the gene of interest at the source.  DNAi therapeutics have the potential to treat cancer and other genetic diseases with an innovative and targeted approach.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and involve significant risks and uncertainties that may cause results to differ materially from those set forth in the statements.

Contact:
Mina Sooch
CEO, ProNAi
248-681-9815
msooch@pronai.com
www.pronai.com

SOURCE ProNAi Therapeutics, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
As organizations abandon the waterfall method of software development for Agile, many are stuck in what Hasan Yasar terms Water-Scrum-Fall. That is, the organization has not effectively embraced Agile and DevOps principles and remains in silos with no links to business goals. Enter Dev...
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, discussed the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is t...
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process t...
Technology integration is complex and an evergreen business challenge for IT teams. Enterprises setup manual & point to point connections to exchange data from business partners. However, data disruptions emerge when the business IT systems expand and prevents organizations from sharin...
SYS-CON Events announced today that SourceForge has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SourceForge is the largest, most trusted destination for Op...
Most large organizations require dozens and sometimes hundreds of specialized software tools to manage the lifecycle of the physical products or software applications they create. It isn’t hard to imagine the monumental waste these organizations incur in attempting to manually coordina...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE